Table 1.
Baseline demographic and clinical patient characteristics
| Characteristic | No. of patients | % |
|---|---|---|
| Total enrolled | 31 | |
| Sex | ||
| Male | 23 | 74 |
| Female | 8 | 26 |
| Median age, y (range) | 64 (44-84) | |
| Race/ethnicity | ||
| White, non-Hispanic | 27 | 87 |
| White, Hispanic | 2 | 7 |
| Black, non-Hispanic | 1 | 3 |
| American Indian or Alaskan Native, non-Hispanic | 1 | 3 |
| Histology | ||
| Follicular lymphoma | 16 | 52 |
| Follicular NHL grade 1 | 7 | 23 |
| Follicular NHL grade 2 | 3 | 10 |
| Follicular NHL grade 3 | 5 | 16 |
| Follicular, NOS | 1 | 3 |
| Marginal zone | 3 | 10 |
| Small lymphocytic lymphoma | 3 | 10 |
| Mantle cell lymphoma | 7 | 23 |
| Lymphoplasmacytic lymphoma | 2 | 6 |
| FLIPI risk group (n = 16) | ||
| Low risk (0-1 risk factors) | 2 | 13 |
| Intermediate risk (2 risk factors) | 5 | 31 |
| High risk (≥ 3 risk factors) | 9 | 56 |
| B symptoms at baseline | 7 | 23 |
| Baseline stage | ||
| I | 1 | 4 |
| II | 5 | 16 |
| III | 14 | 45 |
| IV | 11 | 35 |
| Prior therapy | ||
| CHOP (+/- R) | 19 | 63 |
| Purine analog chemotherapy (fludarabine +/- R) | 6 | 20 |
| ASCT | 6 | 20 |
| Radioimmunotherapy | 9 | 30 |
| Bortezomib | 2 | 7 |
| Median no. of prior regimens | 4 | |
| Rituximab refractory | 10 | 33* |
NOS indicates not otherwise specified; FLIPI, Follicular Lymphoma International Prognostic Index; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; and ASCT, autologous stem cell transplantation.
*
Thirty-three percent of the 30 patients who had received prior rituximab therapy.